Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:CELU

Celularity Q1 2025 Earnings Report

Celularity logo
$1.38 +0.03 (+2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 -0.02 (-1.81%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Celularity EPS Results

Actual EPS
-$1.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$5.74 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q1 2025
Date
8/29/2025
Time
After Market Closes
Conference Call Date
Friday, August 29, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Celularity's Q2 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Celularity's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Celularity Earnings Headlines

Viome CEO Jain to join board of directors at Florham Park-based Celularity
October 1 at 1:48 PM  |  roi-nj.comR
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
September 30 at 11:57 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372229/0/en/celularity-highlights-anticipated-quarter-one-2027-opening-of-fontaine-vitale-as-strategic-partner.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 1 at 1:00 AM  |  Stansberry Research (Ad)
Celularity (NASDAQ:CELU) Releases Quarterly Earnings Results
September 30 at 7:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31069017
Celularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
September 29 at 10:19 PM  |  marketscreener.comM
Celularity Inc. ernennt Naveen Jain zum Verwaltungsratsmitglied
September 29 at 10:19 PM  |  de.marketscreener.comD
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs. The company has also developed placental-derived biomaterial products intended to support wound care and tissue repair.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. The company was founded by Robert J. Hariri, M.D., Ph.D., who has served in senior leadership roles, including chief executive officer and chairman. Its products and clinical programs are intended for use in the United States and other markets where regulatory authorization or clinical development is available.

View Celularity Profile
Earnings Tools